Macrocyclic Metal Complexes for Superoxide Dismutation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural superoxide dismutase enzymes face challenges such as lack of oral activity, short half-lives, and immunogenicity, limiting their therapeutic efficacy in reducing superoxide levels in inflammatory diseases and disorders.
Innovation Solution
Development of manganese or iron complexes with conjugated unsaturated 1,5-diaza macrocyclic ligands that form stable complexes, providing potent superoxide dismutase mimetic activity and improved stability for in vivo applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural superoxide dismutase enzymes are used as therapeutic agents, then superoxide levels are reduced, but oral activity is lacking and half-life is short
Solution Approach 1:
The patent creates synthetic SOD mimetics that copy the catalytic function of natural SOD enzymes using non-proteinaceous catalysts. These mimetics replicate the superoxide dismutation activity while overcoming the biological limitations of protein enzymes, achieving both oral bioavailability and extended half-life through small molecule chemistry rather than polypeptide-based therapy.
Solution Approach 2:
The patent modifies the chemical structure by changing from protein-based enzymes to small molecule complexes with specific metal centers (Fe, Mn, Co, Cu). This parameter change in molecular size and chemical nature enables oral administration and extends half-life while maintaining catalytic activity. The complexes feature specific ligand arrangements that optimize both activity and stability.
2Reliability
If natural superoxide dismutase enzymes are used as therapeutic agents, then superoxide levels are reduced, but immunogenicity occurs
Solution Approach 1:
The patent replaces protein-based enzymes with synthetic small molecule complexes that copy the catalytic function without the immunogenic properties of proteins. By using inorganic metal centers coordinated by organic ligands, the therapy avoids T-cell mediated immunity and antibody formation that plague protein enzyme therapies.
Solution Approach 2:
The patent employs small molecule complexes that are chemically stable and metabolically inert, effectively treating the condition without triggering immune responses. These molecules are designed to be biologically inactive themselves, serving only as catalysts, thereby avoiding the immunogenicity associated with foreign protein enzymes.
3Reliability
If natural superoxide dismutase enzymes are used as therapeutic agents, then superoxide levels are reduced, but oral activity is lacking
Solution Approach 1:
The patent transitions from protein-based enzymes to small molecule SOD mimetics that can be orally administered. These small molecules pass through the gastrointestinal tract and enter circulation without requiring injection, providing both oral bioavailability and sustained superoxide reduction activity throughout the body.
Solution Approach 2:
The patent changes the molecular size and chemical properties from large proteins to small metal complexes with organic ligands. This parameter change enables oral absorption and distribution, allowing the therapy to be administered via tablets or capsules while maintaining effective superoxide dismutation activity in target tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new macrocyclic ligands create stable complexes with metals like Mn and Fe, offering enhanced superoxide dismutase mimetic activity, longer half-life, and oral bioavailability, effectively reducing oxidative damage and inflammation in various conditions.
Implementation Method 1
The enzyme superoxide dismutase catalyzes the conversion of superoxide into oxygen and hydrogen peroxide... manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide
Data Source
AI summary
The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide. It also relates to methods of using these complexes to reduce the concentration or the effects of superoxide, pharmaceutical compositions comprising these compounds or their metal complexes, and methods of treating conditions associated with excessive superoxide activity.